Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis

Phase 3

Recruiting

• Conditions: Cerebral venous thrombosis.; Cerebral infarction due to thrombosis of unspecified precerebral artery; I63.00

• Registration Number: IRCT20120215009014N451
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Age 18 to 80 years
Cerebral venous thrombosis

Exclusion Criteria

Contraindication o anticoagulant therapy
Brain tumor

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional impairment. Timepoint: 90 days after intervention. Method of measurement: Using modified Rankin Scale (mRS).

Secondary Outcome Measures

Name	Time	Method
Complication of cerebral hemorrhage. Timepoint: During the 6-month follow-up period. Method of measurement: Using brain CT scan.